Compass Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to discovering and developing proprietary antibody-based therapeutics. Founded in 2014 and headquartered in Boston, Massachusetts, the company focuses on the complex relationship between angiogenesis, the immune system, and tumor growth. Compass leverages its proprietary StitchMabs™ and common-light-chain platforms to design and develop novel bispecific and monoclonal antibodies with high manufacturability. Its pipeline is structured to target multiple critical biological pathways required for an effective anti-tumor response, including the modulation of microvasculature via angiogenesis-targeted agents, induction of potent immune responses, and alleviation of tumor-driven immunosuppressive mechanisms.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead DLL4 x VEGF-A bispecific antibody candidate beyond biliary tract cancer into a broader set of DLL4+ solid tumors, including colorectal, ovarian, gastric, renal, and hepatocellular cancers.
Expected impact: Aims to establish therapeutic efficacy in multiple high-unmet-need solid tumor indications, expanding the addressable market.
Initiating and accelerating the Phase 1 dose-escalation study of CTX-10726, a novel PD-1 x VEGF-A bispecific antibody, in patients with locally advanced or metastatic solid tumors who have failed standard therapies.
Expected impact: Aims to demonstrate superior tumor control and PD-1/VEGF-A inhibition compared to existing monotherapies and competitive bispecifics.
Enrolling patients in Phase 1 expansion cohorts for CTX-8371, a PD-1 x PD-L1 bispecific antibody, targeting non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and Hodgkin lymphoma.
Expected impact: Designed to generate deep, durable anti-tumor responses in patients who have progressed on approved checkpoint inhibitors.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Enables the evaluation of tovecimig in combination with first-line standard-of-care regimens (gemcitabine, cisplatin, and durvalumab) in biliary tract cancer patients.
Terms: Not explicitly disclosed; typically involves drug supply and partial funding support.